All News
Filter News
Found 806,227 articles
-
Symmetry Surgical, Inc. Acquires The O.R. Company
1/8/2020
Symmetry Surgical, Inc. ("Symmetry"), is pleased to announce that it has completed its acquisition of The O.R. Company.
-
77 Teams Worldwide Advance in the $10M ANA Avatar XPRIZE Competition
1/8/2020
Qualifying Teams Hail From 19 Countries
-
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
1/8/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for a Phase 2 trial of edasalonexent, a novel NF-kB inhibitor, in non-ambulatory DMD patients
-
Accuray CyberKnife® System Provides Excellent Disease Control for Men with Recurrent Prostate Cancer, a Medical Condition with Few Viable Treatment Options
1/8/2020
Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife® System provided excellent disease control with low rates of toxicity in men with locally recurrent prostate cancer after previous treatment with radiation therapy.
-
Solidia Technologies and Uncountable Accelerate Development of Next-Generation Concrete Manufacturing with Data Science and AI
1/8/2020
New enterprise software platform brings data revolution to cement and concrete
-
Turnstone Appoints Saryah Azmat as Senior Vice President of Business Development and Corporate Strategy
1/8/2020
Ms. Azmat will lead identification, evaluation and execution of new business development opportunities and development of the company’s corporate growth strategy.
-
AllerGenis to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
AllerGenis, a data-driven precision diagnostics company focused on food allergies, today announced that CEO Jim Garner will be presenting during the Biotech Showcase at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
-
RxGen Rebrands as Virscio to Reflect Corporate Growth and Enhanced Focus on Comprehensive Suite of Preclinical Research Offerings and Capabilities
1/8/2020
RxGen, a translational research company ensuring definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced it is rebranding as Virscio (vir’sio) to reflect substantial expansion of capabilities since inception and growth into a leading nonhuman primate preclinical research organization.
-
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
1/8/2020
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study.
-
Komodo Health Secures $50 Million in Series C Funding Led by Andreessen Horowitz, Joined by Oak HC/FT
1/8/2020
Investment enables expansion of Komodo’s end-to-end analytics platform and products built atop the most complete healthcare dataset
-
Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense
1/8/2020
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced the Department of Defense (DoD) has awarded APT a contract of $10.2 million for the development of PhageBankTM a personalized bacteriophage therapeutic for the treatment of bacterial infections.
-
Former BCBSA Chief Medical Officer Launches Knowality Firm for Health Care Startups
1/8/2020
Dr. Trent Haywood, former president of the Blue Cross Blue Shield Institute and former chief medical officer of the Blue Cross Blue Shield Association (BCBSA), today announced the launch of a venture services company that will connect health care startups with payers and providers.
-
MercachemSyncom Closes Acquisition of Alcami Weert
1/8/2020
Expands portfolio of chemistry services from compound design to clinical proof of concept
-
Vyaire Medical Enters Exclusive, Five-Year Agreement to Distribute Spirosure's Fenom Pro™ Asthma Monitor in Multiple Countries
1/8/2020
Spirosure's Fenom Pro is one of two FDA-cleared devices that measures FeNO, the most established biomarker for diagnosing and managing asthma.
-
Pliant Therapeutics Appoints Gayle Crowell to its Board of Directors
1/8/2020
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Gayle Crowell to its board of directors as an independent director.
-
Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector
1/8/2020
PharmaJet, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published.
-
Translational Medicine Accelerator and Cyclica Partner to Form Rare Diseases Medicine Accelerator to Advance the Discovery of Novel Therapies for Rare Diseases
1/8/2020
Up to 10% of the world’s population suffers from one or more of the 10,000 estimated rare diseases defined by the Monarch Disease Ontology, resulting in chronic, progressive, and terminal medical conditions that are often misdiagnosed or clinically mismanaged.
-
BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/8/2020
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
-
Researchers Surprised by High Levels of Alcohol Consumption among Cancer Survivors
1/8/2020
First-ever large study on drinking habits of cancer survivors--published in JNCCN--finds more than a third exceed moderate drinking levels, one in five engage in binge drinking [08-January-2020] PLYMOUTH MEETING, Pa. , Jan. 8, 2020 /PRNewswire/ -- New research in the January 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network uses data from
-
Global In-Vitro Toxicity Testing Market 2019-2023 | Evolving Opportunities with Abbott Laboratories and Agilent Technologies Inc. | Technavio
1/8/2020
Technavio has announced its latest market research report titled global in-vitro toxicity testing market 2019-2023.